Stephen Stemkowski
Overview
Explore the profile of Stephen Stemkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Antol D, Casebeer A, Khoury R, Michael T, Renda A, Hopson S, et al.
J Patient Rep Outcomes
. 2021 Mar;
5(1):25.
PMID: 33687575
No abstract available.
2.
DeClue R, Antol D, Casebeer A, Michael T, Sehman M, Renda A, et al.
Am J Manag Care
. 2020 Jun;
26(6):e191-e197.
PMID: 32549069
Objectives: The goal of this study was to establish a claims-based mechanism for identifying patients with metastatic non-small cell lung cancer (mNSCLC) and high levels of patient-reported cancer-related symptoms who...
3.
Li Y, Lim J, Stemkowski S, Kaila S, Renda A, Shaikh A
Am J Manag Care
. 2020 Apr;
26(4):e106-e112.
PMID: 32270987
Objectives: Triple therapy is indicated for patients with very severe chronic obstructive pulmonary disease (COPD). Use of this treatment in the appropriate patient population is important to ensure optimal outcomes....
4.
Casebeer A, Antol D, Hopson S, Khoury R, Renda A, Parikh A, et al.
Popul Health Manag
. 2019 Jun;
22(5):440-448.
PMID: 31211653
This study investigated factors associated with patient-reported health-related quality of life (HRQoL) using the Centers for Disease Control and Prevention's Healthy Days tool for patients with Medicare Advantage undergoing treatment...
5.
Stanford R, Lau M, Li Y, Stemkowski S
J Manag Care Spec Pharm
. 2018 Dec;
25(1):58-69.
PMID: 30589629
Background: Chronic obstructive pulmonary disease (COPD) exacerbations can accelerate disease progression and lead to higher health care costs. To improve patient survival and reduce cost, risk assessment measures should be...
6.
Casebeer A, Antol D, Hopson S, Khoury R, Renda A, Parikh A, et al.
Popul Health Manag
. 2018 Dec;
PMID: 30562143
The article entitled, "Using the Healthy Days Measure to Assess Factors Associated with Poor Health-Related Quality of Life for Patients with Metastatic Breast, Lung, or Colorectal Cancer Enrolled in a...
7.
Tao Z, Li Y, Stemkowski S, Johnson K, Acosta C, Zhang D, et al.
Vaccines (Basel)
. 2018 Nov;
6(4).
PMID: 30469449
Herpes zoster (HZ) vaccination is approved for adults aged 50+ for the prevention of HZ, but it is underutilized. The objective of this study was to evaluate the association between...
8.
Lane D, Stemkowski S, Stanford R, Tao Z
J Manag Care Spec Pharm
. 2018 Oct;
24(11):1165-1172.
PMID: 30362922
Background: Evidence suggests that real-world treatment patterns of chronic obstructive pulmonary disease (COPD) do not always follow evidence-based treatment recommendations such as those of the Global Initiative for Chronic Obstructive...
9.
Antol D, Casebeer A, Khoury R, Michael T, Renda A, Hopson S, et al.
J Patient Rep Outcomes
. 2018 Oct;
2:29.
PMID: 30294709
Background: Studies have demonstrated that comorbidities compound the adverse influence of cancer on health-related quality of life (HRQoL). Comorbidities adversely impact adherence to cancer treatment. Additionally, adherence to medications for...
10.
Casebeer A, Antol D, DeClue R, Hopson S, Li Y, Khoury R, et al.
J Manag Care Spec Pharm
. 2018 May;
24(6):554-564.
PMID: 29799325
Background: Guideline-recommended therapy for metastatic non-small cell lung cancer (mNSCLC) encourages evidence-based treatment; however, there is a knowledge gap regarding the influence of guideline-recommended initiation of therapy on outcomes and...